

Rating Update

November 29, 2023 | Mumbai

Auro Laboratories Limited

Update as on November 29, 2023

This update is provided in continuation of the rating rationale below.

The key rating sensitivity factors for the rating include:

Upward Factors:

- Sustenance in revenue and significant improvement in operating margin above 14%
- Sustenance of financial risk profile and liquidity

Downward Factors:

- Fall in revenue or profitability margin below 5%, leading to lower net cash accrual
- Debt-funded capital expenditure or stretched working capital cycle, leading to significant weakening in the financial risk profile and liquidity

CRISIL Ratings has a policy of keeping its accepted ratings under constant and ongoing monitoring and review. Accordingly, CRISIL Ratings seeks regular updates from companies on the business and financial performance. CRISIL Ratings is, however, awaiting adequate information from Auro Laboratories Limited (ALL) which will enable us to carry out the rating review. CRISIL Ratings will continue provide updates on relevant developments from time to time on this credit.

CRISIL Ratings also identifies information availability risk as a key credit factor in the rating assessment as outlined in its criteria 'Information Availability Risk in Credit Ratings'.

About the Company

Incorporated in 1989 by Mr Sharat Deorah and Mr Siddhartha Deorah, ALL manufactures APIs, majorly Metformin HCL. It is listed on the Bombay Stock Exchange. Its facility is located in Tarapur, Maharashtra.

Note for Media:

This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.

About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).

CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").

For more information, visit www.crisilratings.com

About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better.

It is India's foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: [TWITTER](#) | [LINKEDIN](#) | [YOUTUBE](#) | [FACEBOOK](#)

CRISIL PRIVACY NOTICE

CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.

DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to: <https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html>.

Please note: This advisory should not be construed as a rating reaffirmation.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: <https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html>

Rating Rationale

May 03, 2023 | Mumbai

Auro Laboratories Limited

Ratings reaffirmed at 'CRISIL BBB-/Negative/CRISIL A3'; rated amount enhanced for Bank Debt

Rating Action

Total Bank Loan Facilities Rated	Rs.47.1 Crore (Enhanced from Rs.30.6 Crore)
Long Term Rating	CRISIL BBB-/Negative (Reaffirmed)
Short Term Rating	CRISIL A3 (Reaffirmed)

Note: None of the Directors on CRISIL Ratings Limited's Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.

1 crore = 10 million

Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its ratings on the bank facilities of Auro Laboratories Limited (ALL) at 'CRISIL BBB-/Negative/CRISIL A3'.

The reaffirmation in outlook reflects weakening of business risk profile marked by decline in operating margin to 6% for 9month ended December 31, 2022, compared to 10.54% for fiscal 2022. This was due to inability to pass on the increased raw material price to customers and due to high freight charges. As per the management, company has revised the contract rates and improvement in operating margins have improved in Q4. Sustenance of improved operating margins would be a key monitorable. Financial profile and liquidity continue to remain adequate.

The ratings continue to reflect the extensive experience of the promoters of ALL in the pharmaceutical industry, diversified and strong customer base and its comfortable financial risk profile. These strengths are partially offset by the large working capital requirement, modest scale of operation amid intense competition and product concentration in revenue.

Analytical Approach

Unsecured loan is treated as debt

Key Rating Drivers & Detailed Description

Strengths:

- **Extensive experience of the promoters:** The three decades of experience of the promoters in the pharmaceutical industry along with support of professionally qualified secondary level management, their in-depth understanding of market dynamics and strong relationships with suppliers and customers in India and abroad should continue to support the business.
- **Diversified and strong customer base:** The large client base partially offsets the customer concentration in revenue with the top five customers accounted for 25-30% of total revenue in fiscal 2022. The company has diversified its geographically presence across various countries such as Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and countries in the United Kingdom accounts for 70-75% revenues, while the remaining comes from the domestic market thereby reducing its geographical concentration risk.
- **Comfortable financial risk profile:** Network remained moderate at Rs.31.48 crore as on March 31, 2022 and limited reliance on outside borrowings kept gearing and total outside liabilities to adjusted network(TOLANW) ratios comfortable at 0.44 time and 0.74 time, respectively as on March 31, 2022. The gearing ratio and TOLANW are estimated at 0.48-0.50 time and 0.70-0.75 time as on March 31, 2023. With no major outflow of capital for dividend, capital structure is expected to remain at similar levels. Debt protection metrics continue to be robust with healthy operating margin as highlighted by interest coverage and net cash accrual to adjusted debt ratios of 6.92 times and 0.28 time, respectively, for fiscal 2022. The interest coverage and net cash accrual to adjusted debt ratios are estimated at 4.35-4.50 times and 0.45-0.55 time, respectively, for fiscal 2023.

Weaknesses:

- **Modest scale of operation amid intense competition and volatile operating margins:** Despite growth, scale of operation remains modest with revenue of Rs 50.9 crore in fiscal 2022. The pharmaceutical industry is highly competitive, which constrains sizeable growth and restricts bargaining power with customers and suppliers, and benefits accruing from economies of scale. Further the operating margins have been volatile between 10-20% over the last 3 fiscal years ended March 31, 2022 and had decline in first nine months of fiscal 2023 to 5.99% from 11.29% in fiscal 2022 on account of sharp increase in freight charges and raw material prices and delays in passing on the same to its customers. Stability and sustenance of operating margins will monitorable over the medium term.
- **Product concentration in revenue:** Nearly 90% of the revenue is derived through Metformin HCL (an active pharmaceutical ingredient). Hence, slowdown in demand or price reduction due to replacement products or regulatory interventions, may impact the business significantly. Product concentration in revenue is likely to reduce with the expected addition of more products. Hence, diversification of product profile and revenue growth will remain key monitorable.
- **Large working capital requirement:** Gross current assets (GCAs) were sizeable at 200 days, as on March 31, 2022, due to receivables of around 99 days and high other current assets, although inventory was moderate at 34 days. An open credit of 60-

90 days is offered to major clients. Payables of 60-90 days support working capital. The management of working capital will remain a key monitorable over the medium term.

Liquidity: Adequate

Cash accrual, expected at Rs.3.0-3.5 crores in fiscal 2023. Cash accruals of Rs 5 - 7.5 crores for fiscals 2024 and 2025 should comfortably cover debt obligation of Rs 0.3-2.9 crore, respectively. Fund-based limit of Rs 9 crore was utilised 63.03% on average during the 12 months through March 2023. Cash and equivalents stood at Rs 12.37 crore as on March 31, 2022.

Outlook: Negative

CRISIL Ratings believes the business risk profile of ALL may remain under pressure over the medium term owing to low profit margin.

Rating Sensitivity factors

Upward Factors:

- Sustenance in revenue and significant improvement in operating margin above 14%
- Sustenance of financial risk profile and liquidity

Downward Factors:

- Fall in revenue or profitability margin below 5%, leading to lower net cash accrual
- Debt-funded capital expenditure or stretched working capital cycle, leading to significant weakening in the financial risk profile and liquidity

About the Company

Incorporated in 1989 by Mr Sharat Deorah and Mr Siddhartha Deorah, ALL manufactures APIs, majorly Metformin HCL. It is listed on the Bombay Stock Exchange. Its facility is located in Tarapur, Maharashtra.

Key Financial Indicators

As on/for the period ended March 31	Unit	9M FY2023	2022	2021
Operating income	Rs crore	39.37	50.91	54.25
Reported profit after tax (PAT)	Rs crore	0.66	2.84	7.18
PAT margin	%	1.68	5.59	13.23
Adjusted debt/adjusted networkth	Times	-	0.44	0.11
Interest coverage	Times	3.10	6.92	26.17

Any other information: Not applicable

Note on complexity levels of the rated instrument:

CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN	Name of the instrument	Date of Allotment	Coupon Rate (%)	Maturity Date	Issue size (Rs. Crore)	Complexity Level	Rating assigned with outlook
NA	Bank Guarantee	NA	NA	NA	0.6	NA	CRISIL A3
NA	Cash Credit	NA	NA	NA	4.5	NA	CRISIL BBB-/Negative
NA	Letter of Credit	NA	NA	NA	5	NA	CRISIL A3
NA	Term Loan	NA	NA	Mar-30	32.04	NA	CRISIL BBB-/Negative
NA	Working Capital Term Loan	NA	NA	NA	0.22	NA	CRISIL BBB-/Negative
NA	Packing Credit	NA	NA	NA	4.5	NA	CRISIL BBB-/Negative
NA	Forward Contract	NA	NA	NA	0.24	NA	CRISIL BBB-/Negative

Annexure - Rating History for last 3 Years

Instrument	Type	Current		2023 (History)		2022		2021		2020		Start of 2020
		Outstanding Amount	Rating	Date	Rating	Date	Rating	Date	Rating	Date	Rating	Rating
Fund Based Facilities	ST/LT	41.5	CRISIL BBB-/Negative / CRISIL A3	22-02-23	CRISIL BBB-/Negative	27-07-22	CRISIL BBB-/Stable	29-11-21	CRISIL BBB-/Stable	27-08-20	CRISIL BBB-/Stable	CRISIL BBB-/Stable
Non-Fund Based Facilities	ST	5.6	CRISIL A3	22-02-23	CRISIL A3	27-07-22	CRISIL A3	29-11-21	CRISIL A3	27-08-20	CRISIL A3	CRISIL A3

All amounts are in Rs. Cr.

Annexure - Details of Bank Lenders & Facilities

Facility	Amount (Rs.Crore)	Name of Lender	Rating
Bank Guarantee	0.6	Indian Bank	CRISIL A3
Cash Credit	4.5	Indian Bank	CRISIL BBB-/Negative
Foreign Exchange Forward	0.24	Indian Bank	CRISIL A3

Letter of Credit	5	Indian Bank	CRISIL A3
Packing Credit	4.5	Indian Bank	CRISIL A3
Term Loan	16.5	Indian Bank	CRISIL BBB-/Negative
Term Loan	15.54	Indian Bank	CRISIL BBB-/Negative
Working Capital Term Loan	0.22	Indian Bank	CRISIL BBB-/Negative

This Annexure has been updated on 03-May-2023 in line with the lender-wise facility details as on 27-Jul-2022 received from the rated entity.

Criteria Details

Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufacturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry

Media Relations	Analytical Contacts	Customer Service Helpdesk
<p>Aveek Datta Media Relations CRISIL Limited M: +91 99204 93912 B: +91 22 3342 3000 AVEEK.DATTA@crisil.com</p> <p>Prakruti Jani Media Relations CRISIL Limited M: +91 98678 68976 B: +91 22 3342 3000 PRAKRUTI.JANI@crisil.com</p> <p>Rutuja Gaikwad Media Relations CRISIL Limited B: +91 22 3342 3000 Rutuja.Gaikwad@ext-crisil.com</p>	<p>Jaya Mirpuri Director CRISIL Ratings Limited D:+91 20 4018 1926 jaya.mirpuri@crisil.com</p> <p>Shalaka Singh Associate Director CRISIL Ratings Limited D:+91 22 3342 3000 Shalaka.Singh@crisil.com</p> <p>Arpit Mittal Manager CRISIL Ratings Limited B:+91 22 3342 3000 Arpit.Mittal@crisil.com</p>	<p>Timings: 10.00 am to 7.00 pm Toll free Number:1800 267 1301</p> <p>For a copy of Rationales / Rating Reports: CRISILratingdesk@crisil.com</p> <p>For Analytical queries: ratingsinvestordes@crisil.com</p>

Note for Media:

This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.

About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).

CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").

For more information, visit www.crisilratings.com

About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better.

It is India's foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: [TWITTER](#) | [LINKEDIN](#) | [YOUTUBE](#) | [FACEBOOK](#)

CRISIL PRIVACY NOTICE

CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.

DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to: <https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html>.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: <https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html>